Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02511 君聖泰醫藥 - B
Listing Date2023/12/22
Listing Price11.500
  • 5.840 -0.240 (-3.947%)    Sink Below Listing Price
  • 15-min delayed, last update: 23/05/2024 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    9 lot
  • One Lot Success Rate

HighTide Therapeutics is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases.


The group have researched and developed in-house a pipeline with five proprietary drug candidates covering nine indications, including five indications that are at clinical stage. Its Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.


As of 4 December 2023, the group held 133 patents and patent applications, including 58 patents and patent applications in relation to its Core Product and held 34 trademarks and trademark applications in the United States, Mainland China, Hong Kong, Europe and United Kingdom.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares24.19M shares
No. of International Offer Shares16.94M shares
No. of HK Offer Shares7.26M shares
Offer Price$11.50
Stock Code2511
Sponsor(s)UBS Securities Hong Kong Limited, Huatai Financial Holdings (Hong Kong) Limited
Underwriter(s)UBS AG Hong Kong Branch, Huatai Financial Holdings (Hong Kong) Limited, CLSA Limited, CMB International Capital Limited, BOCOM International Securities Limited, Yue Xiu Securities Company Limited, CCB International Capital Limited, Fosun International Securities Limited, Goldlink Securities Limited, I Win Securities Limited, Shenwan Hongyuan Securities (H.K.) Limited, uSmart Securities Limited, Winbull Securities International (HK) Limited
Application PeriodDec 14 (Thu) - noon, Dec 19 (Tue)
Price Determination Date--
Result Announcement DateOn or before Dec 21 (Thu)
Result Announcement DateOn or before Dec 21 (Thu)
Result Announcement DateOn or before Dec 22 (Fri)
Dealings in Shares commence onDec 22, 2023. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$11.50
NAV / share ($)$1.91 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 11.50, the net proceeds raised would be HKD 194.10M, of which
80% : Clinical development activities and registration filings of Core Product HTD1801
5% : Research and development, drug production for the clinical studies of product candidate HTD1804 for obesity
10% : For the early drug discovery and development of other drug candidates
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.